Treprostinil in Advanced Experimental Pulmonary Hypertension: Beneficial Outcome Without Reversed Pulmonary Vascular Remodeling.
From: Department of Pediatrics, Division of Pediatric Cardiology, Beatrix Children’s Hospital, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. m.e.van.albada@med.umcg.nl
Journal of cardiovascular pharmacology
- Publish Date: Nov 2006
- ISSN: 0160-2446
- Volume: 48
- Issue: 5
- Pages: 249-54
- Medium: Print
- Language: English
- Citation (JAMA): van Albada Mirjam E, van Veghel Richard, Cromme-Dijkhuis Adri H, et al. Treprostinil in Advanced Experimental Pulmonary Hypertension: Beneficial Outcome Without Reversed Pulmonary Vascular Remodeling.. J. Cardiovasc. Pharmacol. Nov 2006;48:249-54
Abstract
INTRODUCTION: Beneficial effects of treprostinil, a stable prostacyclin analogue, were demonstrated in patients with pulmonary arterial hypertension (PAH). Although regression of pulmonary vascular remodeling has been suggested as therapeutic mechanism, its mode of action remains unknown. METHODS: Flow-associated PAH was created in rats by injection of monocrotaline (60 mg/kg) combined with an abdominal aortocaval shunt. Subsequently, rats were treated with subcutaneous treprostinil (50 ng/kg/min, treated; n = 8) or saline (untreated; n = 9). A control group underwent sham-surgery (n = 8). Animals were sacrificed at symptoms of cardiac failure, together with their matched controls. RESULTS: Dyspnea and weight loss determined the moment of sacrifice in 8/9 untreated animals (89%) versus in one of eight treated animals (13%; log-rank test survival curves; P = 0.02). Mean pulmonary arterial pressure increased in the model (42 +/- 2 mm Hg in untreated vs. 18 +/- 1 in controls; P < 0.01) and decreased by 8 mm Hg after therapy (34 +/- 3 mm Hg, P = 0.04 vs. untreated). No effects of treatment on right ventricular hypertrophy could be demonstrated. Quantitative morphometry of pre- and intra-acinar pulmonary arteries revealed no effects of treatment on vessel histopathology. CONCLUSIONS: Treprostinil treatment improved clinical course and ameliorated symptoms of heart failure in a model of advanced PAH. However, beneficial effects were not associated with reversed structural remodelling of the pulmonary vasculature.
Mesh Headings (Keywords): Animals, Blood Pressure, Disease Models, Animal, Epoprostenol, Hypertension, Pulmonary, Pulmonary Circulation, Rats, Rats, Wistar, Treatment Outcome
Check for Full Text / PubMed Unique Identifier (PMID): 17110807
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.